Jun. 07, 2025 11:36 PM ETAkebia Therapeutics, Inc. (AKBA) StockMLYS, CDNA, RCUS, AKBAStella Mwende1.98K Followers(9min)SummaryAkebia Therapeutics is rated a hold, as shares trade near fair value and management is optimistic about Vafseo's expanded rollout by the end of 2025.Auryxia, Akebia's main revenue driver, lost exclusivity in March 2025, with a generic now on the market, posing a risk to future revenues.Vafseo's strong initial uptake and expected adoption by large dialysis organizations could drive revenue growth into 2026 and beyond.Akebia's robust cash position supports operational growth, but near-term upside is limited due to generic competition and current valuation.mi-viri/iStock via Getty ImagesBiopharmaceutical company Akebia Therapeutics (NASDAQ:AKBA) is emerging as a remarkable opportunity for investors looking to delve into the healthcare sector. The stock is up 271.03% (YoY) and is trading at a new 52-week high of $4.0. It has a marketThis article was written byStella Mwende1.98K FollowersI have more than five years experience in the financial industry. I focus mostly in the commodities, foreign exchange and cryptocurrencies. I also write on general issues like equity research, economics and geopolitics.Fellow contributor Crispus Nyaga is my colleague.Analyst’s Disclosure:I/we have a beneficial long position in the shares of AKBA either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.CommentsRecommended For You